Atriva Therapeutics Gmbh

Westfaelische Wilhelms-universitaet Muenster

Activaero Gmbh

Ventaleon Gmbh

Stephan Ludwig

Oliver Planz

Christina Ehrhardt

Stephan Pleschka

Hans-Harald Sedlacek

Gerhard Scheuch

Michael Schindler

Eike-Roman Hrincius

Julia Koch-heier

Helen Elisa Hoffmann

The present invention relates to PD-0184264 for use in a method for the prophylaxis and/or treatment of a co-infection comprising a bacterial infection and an influenza vims infection or a viral or bacterial infection alone. Also provided are compositions comprising such inhibitors for use in the prophylaxis and/or treatment of a co-infection comprising a bacterial infection and an influenza virus infection or a bacterial or viral infection alone.

MEK-inhibitor for the treatment of viral and bacterial infections

The present invention relates to MEK inhibitor, p38 inhibitor and/or NF&#x3ba;B inhibitor for use in a method for the prophylaxis and/or treatment of a co-infection comprising a bacterial infection and an influenza virus infection or a bacterial infection alone. Also provided are compositions comprising such inhibitors for use in the prophylaxis and/or treatment of a co-infection comprising a bacterial infection and an influenza virus infection or a bacterial infection alone. In addition an in vitro test system, wherein the test system comprises cultured cells infected with an influenza virus and aor with aalone is provided.

Novel-anti-infective strategy against influenza virus andcoinfections

The present invention relates to MEK inhibitor, p38 inhibitor and/or NF&#x3ba;B inhibitor for use in a method for the prophylaxis and/or treatment of a co-infection comprising a bacterial infection and an influenza virus infection or a bacterial infection alone. Also provided are compositions comprising such inhibitors for use in the prophylaxis and/or treatment of a co-infection comprising a bacterial infection and an influenza virus infection or a bacterial infection alone. In addition an in vitro test system, wherein the test system comprises cultured cells infected with an influenza virus and a bacterium or with a bacterium alone is provided.

Anti-infective strategy against influenza virus andcoinfections

The invention provides a combination of an isolated peptide or peptidomimetic that includes the sequence of SEQ ID NO: 1 or a homolog thereof, and an isolated peptide or peptidomimetic that includes the sequence of SEQ ID NO: 2. The invention also provides a method of treating a BCR-ABL associated disease or a c-ABL associated disease in a subject. The method is based on the use of the aforementioned combination of one or more isolated peptides or peptidomimetics.

Methods and peptides for preventing and treating a BCR-ABL and a C-ABL associated disease

The present invention relates to MEK inhibitors that are capable of displaying one or more beneficial therapeutic effects. The MEK inhibitors can be used in the prevention and/or treatment of viral infection. MEK inhibitors in combination with neuraminidase inhibitor compounds are capable of displaying one or more beneficial therapeutic effects in the treatment of viral diseases.

MEK inhibitors in the treatment of virus diseases

The invention relates to a method of use of a composition comprising a salt of the o-acetylsalicylic acid with a basic amino acid for producing a pharmaceutical composition for the prophylaxis or treatment of viral infections of humans or of animals, in particular mammals and birds.

Use of salt of an acetylsalicylic acid for the treatment of viral infections

The invention relates to the use preferably of at least one active ingredient for the prophylaxis or therapy of a viral disease, wherein this active ingredient inhibits at least one component of the cellular signal transduction pathway for the activation of the transcription factor NF-kB such that virus multiplication is inhibited. The present invention relates furthermore to the local, preferably aerogenic, administration of the active ingredient according to the invention for inhibiting virus multiplication. The active ingredient according to the invention may be combined with at least one further antivirally effective substance for the prophylaxis or therapy of a viral disease.

Growing community of inventors

Muenster, Germany

Stephan Ludwig